{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:54:54Z","timestamp":1790456094831,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K14789"],"award-info":[{"award-number":["JP23K14789"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K07417"],"award-info":[{"award-number":["JP21K07417"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030953","name":"Tokyo Metropolitan Institute for Geriatrics and Gerontology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030953","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although \u03b1-synuclein seed amplification assays (\u03b1-syn SAA) are promising, its sensitivity may be affected by heterogeneity among patients with Lewy body disease (LBD). We evaluated whether \u03b1-syn SAA sensitivity is affected by patient heterogeneity, using <jats:sup>123<\/jats:sup>I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in early drug-na\u00efve patients. Thirty-four patients with clinically established or probable Parkinson\u2019s disease (PD) and seven with dementia with Lewy bodies (DLB) or prodromal DLB were included. While 85.2% of patients with abnormal cardiac MIBG were \u03b1-syn SAA positive, only 14.3% were positive among those with normal scans. Logistic regression analysis showed that MIBG positivity was the only significant variable associated with \u03b1-syn SAA positivity (odds ratio 74.2 [95% confidence interval 6.1\u2013909]). Although \u03b1-syn SAA is sensitive for LBD in patients with abnormal MIBG, the sensitivity may be lower in those with normal MIBG. Further studies are necessary to evaluate the association between patient heterogeneity and \u03b1-syn SAA sensitivity.<\/jats:p>","DOI":"10.1038\/s41531-024-00806-y","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T11:03:10Z","timestamp":1729508590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["\u03b1-synuclein seed amplification assay sensitivity may be associated with cardiac MIBG abnormality among patients with Lewy body disease"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-0634","authenticated-orcid":false,"given":"Masanori","family":"Kurihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-8710","authenticated-orcid":false,"given":"Katsuya","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3497-4714","authenticated-orcid":false,"given":"Keiko","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Ohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9496-2590","authenticated-orcid":false,"given":"Masashi","family":"Kameyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-5314","authenticated-orcid":false,"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"806_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm.2294","volume":"17","author":"R Atarashi","year":"2011","unstructured":"Atarashi, R. et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat. Med. 17, 175\u2013178 (2011).","journal-title":"Nat. Med."},{"key":"806_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812\u2013818 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"806_CR3","first-page":"3916","volume":"55","author":"K Sano","year":"2018","unstructured":"Sano, K. et al. Prion-Like Seeding of Misfolded alpha-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC. Mol. Neurobiol. 55, 3916\u20133930 (2018).","journal-title":"Mol. Neurobiol."},{"key":"806_CR4","doi-asserted-by":"publisher","first-page":"703984","DOI":"10.3389\/fnagi.2021.703984","volume":"13","author":"T Nakagaki","year":"2021","unstructured":"Nakagaki, T., Nishida, N. & Satoh, K. Development of alpha-synuclein real-time quaking-induced conversion as a diagnostic method for alpha-synucleinopathies. Front Aging Neurosci. 13, 703984 (2021).","journal-title":"Front Aging Neurosci."},{"key":"806_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","volume":"10","author":"A Grossauer","year":"2023","unstructured":"Grossauer, A. et al. alpha-synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-A systematic review and meta-analysis. Mov. Disord. Clin. Pract. 10, 737\u2013747 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"806_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 140, 49\u201362 (2020).","journal-title":"Acta Neuropathol."},{"key":"806_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","volume":"20","author":"A Iranzo","year":"2021","unstructured":"Iranzo, A. et al. Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 20, 203\u2013212 (2021).","journal-title":"Lancet Neurol."},{"key":"806_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"806_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"806_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"806_CR11","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JPD-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer, P. & Van Den Berge, N. Brain-first versus gut-first Parkinson\u2019s disease: a hypothesis. J. Parkinsons Dis. 9, S281\u2013S295 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"806_CR12","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"806_CR13","doi-asserted-by":"publisher","first-page":"105557","DOI":"10.1016\/j.nbd.2021.105557","volume":"161","author":"P Borghammer","year":"2021","unstructured":"Borghammer, P. et al. Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiol. Dis. 161, 105557 (2021).","journal-title":"Neurobiol. Dis."},{"key":"806_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41531-022-00436-2","volume":"8","author":"P Borghammer","year":"2022","unstructured":"Borghammer, P. et al. A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 166 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"806_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00702-023-02633-6","volume":"130","author":"P Borghammer","year":"2023","unstructured":"Borghammer, P. The brain-first vs. body-first model of Parkinson\u2019s disease with comparison to alternative models. J. Neural Transm. (Vienna) 130, 737\u2013753 (2023).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"806_CR16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"806_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz, M. et al. Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 74, 163\u2013172 (2017).","journal-title":"JAMA Neurol."},{"key":"806_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman, B. R. et al. Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. Acta Neuropathol. Commun. 6, 7 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"806_CR19","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/acn3.50897","volume":"6","author":"M Bongianni","year":"2019","unstructured":"Bongianni, M. et al. alpha-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann. Clin. Transl. Neurol. 6, 2120\u20132126 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"806_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11481-019-09835-4","volume":"14","author":"S Manne","year":"2019","unstructured":"Manne, S. et al. Ultrasensitive detection of aggregated alpha-synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-QuIC assay: new high-throughput neuroimmune biomarker assay for Parkinsonian disorders. J. Neuroimmune Pharm. 14, 423\u2013435 (2019).","journal-title":"J. Neuroimmune Pharm."},{"key":"806_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz, M. et al. Discriminating alpha-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578, 273\u2013277 (2020).","journal-title":"Nature"},{"key":"806_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ana.25824","volume":"88","author":"W Singer","year":"2020","unstructured":"Singer, W. et al. Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from lewy body synucleinopathies. Ann. Neurol. 88, 503\u2013512 (2020).","journal-title":"Ann. Neurol."},{"key":"806_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar, C. et al. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 62 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"806_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-021-01276-6","volume":"9","author":"K Brockmann","year":"2021","unstructured":"Brockmann, K. et al. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 175 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"806_CR25","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/mds.28651","volume":"36","author":"A Mammana","year":"2021","unstructured":"Mammana, A. et al. RT-QuIC detection of pathological alpha-synuclein in skin punches of patients with Lewy body disease. Mov. Disord. 36, 2173\u20132177 (2021).","journal-title":"Mov. Disord."},{"key":"806_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/acn3.51280","volume":"8","author":"CD Orru","year":"2021","unstructured":"Orru, C. D. et al. A rapid alpha-synuclein seed assay of Parkinson\u2019s disease CSF panel shows high diagnostic accuracy. Ann. Clin. Transl. Neurol. 8, 374\u2013384 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"806_CR27","doi-asserted-by":"publisher","first-page":"fcab045","DOI":"10.1093\/braincomms\/fcab045","volume":"3","author":"D Perra","year":"2021","unstructured":"Perra, D. et al. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Commun. 3, fcab045 (2021).","journal-title":"Brain Commun."},{"key":"806_CR28","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1212\/WNL.0000000000012438","volume":"97","author":"M Rossi","year":"2021","unstructured":"Rossi, M. et al. Diagnostic value of the CSF alpha-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 97, e930\u2013e940 (2021).","journal-title":"Neurology"},{"key":"806_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo, M. J. et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol. Commun. 9, 179 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"806_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00401-021-02288-1","volume":"141","author":"A Sokratian","year":"2021","unstructured":"Sokratian, A. et al. Heterogeneity in alpha-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia. Acta Neuropathol. 141, 547\u2013564 (2021).","journal-title":"Acta Neuropathol."},{"key":"806_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40478-022-01388-7","volume":"10","author":"S Hall","year":"2022","unstructured":"Hall, S. et al. Performance of alphaSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathol. Commun. 10, 90 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"806_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00401-005-0995-7","volume":"109","author":"S Orimo","year":"2005","unstructured":"Orimo, S. et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 109, 583\u2013588 (2005).","journal-title":"Acta Neuropathol."},{"key":"806_CR33","doi-asserted-by":"publisher","first-page":"e1648","DOI":"10.1212\/WNL.0000000000200110","volume":"98","author":"T Matsubara","year":"2022","unstructured":"Matsubara, T. et al. Autopsy validation of the diagnostic accuracy of (123)I-metaiodobenzylguanidine myocardial scintigraphy for Lewy body disease. Neurology 98, e1648\u2013e1659 (2022).","journal-title":"Neurology"},{"key":"806_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1750-3639.2005.tb00097.x","volume":"15","author":"T Amino","year":"2005","unstructured":"Amino, T. et al. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 15, 29\u201334 (2005).","journal-title":"Brain Pathol."},{"key":"806_CR35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.parkreldis.2012.01.009","volume":"18","author":"S Orimo","year":"2012","unstructured":"Orimo, S., Suzuki, M., Inaba, A. & Mizusawa, H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson\u2019s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 18, 494\u2013500 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"806_CR36","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s00259-019-04480-8","volume":"47","author":"T Nihashi","year":"2020","unstructured":"Nihashi, T., Ito, K. & Terasawa, T. Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis. Eur. J. Nucl. Med Mol. Imaging 47, 1984\u20131997 (2020).","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"806_CR37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/jnnp-2015-310327","volume":"86","author":"K Tsujikawa","year":"2015","unstructured":"Tsujikawa, K. et al. Chronological changes of 123I-MIBG myocardial scintigraphy and clinical features of Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 86, 945\u2013951 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"806_CR38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/RLU.0000000000002424","volume":"44","author":"DW Ryu","year":"2019","unstructured":"Ryu, D. W. et al. Initial versus follow-up sequential myocardial 123I-MIBG scintigraphy to discriminate Parkinson disease from atypical Parkinsonian syndromes. Clin. Nucl. Med 44, 282\u2013288 (2019).","journal-title":"Clin. Nucl. Med"},{"key":"806_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-020-02233-8","volume":"141","author":"ZI Tanei","year":"2021","unstructured":"Tanei, Z. I. et al. Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. Acta Neuropathol. 141, 25\u201337 (2021).","journal-title":"Acta Neuropathol."},{"key":"806_CR40","doi-asserted-by":"publisher","unstructured":"Samudra, N. et al. Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort. Alzheimers Dement https:\/\/doi.org\/10.1002\/alz.13799 (2024).","DOI":"10.1002\/alz.13799"},{"key":"806_CR41","doi-asserted-by":"publisher","first-page":"907293","DOI":"10.3389\/fnagi.2022.907293","volume":"14","author":"MK Just","year":"2022","unstructured":"Just, M. K. et al. Alpha-synuclein strain variability in body-first and brain-first synucleinopathies. Front Aging Neurosci. 14, 907293 (2022).","journal-title":"Front Aging Neurosci."},{"key":"806_CR42","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mds.29317","volume":"38","author":"S Virameteekul","year":"2023","unstructured":"Virameteekul, S., Revesz, T., Jaunmuktane, Z., Warner, T. T. & De Pablo-Fernandez, E. Clinical diagnostic accuracy of Parkinson\u2019s disease: where do we stand? Mov. Disord. 38, 558\u2013566 (2023).","journal-title":"Mov. Disord."},{"key":"806_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"806_CR44","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith, I. G. et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 94, 743\u2013755 (2020).","journal-title":"Neurology"},{"key":"806_CR45","doi-asserted-by":"publisher","first-page":"e1009","DOI":"10.1212\/WNL.0000000000201647","volume":"100","author":"M Kurihara","year":"2023","unstructured":"Kurihara, M. et al. CSF P-Tau181 and other biomarkers in patients with neuronal intranuclear inclusion disease. Neurology 100, e1009\u2013e1019 (2023).","journal-title":"Neurology"},{"key":"806_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40478-024-01758-3","volume":"12","author":"M Kurihara","year":"2024","unstructured":"Kurihara, M. et al. Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Abeta42 in Alzheimer\u2019s disease and other neurodegenerative diseases. Acta Neuropathol. Commun. 12, 48 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"806_CR47","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3233\/JAD-240185","volume":"99","author":"M Kurihara","year":"2024","unstructured":"Kurihara, M. et al. Relationship Between Cerebrospinal Fluid Alzheimer\u2019s Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review. J. Alzheimers. Dis. 99, 1077\u20131092 (2024).","journal-title":"J. Alzheimers. Dis."},{"key":"806_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00702-023-02611-y","volume":"130","author":"R Goto","year":"2023","unstructured":"Goto, R. et al. Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes. J. Neural Transm. (Vienna) 130, 513\u2013520 (2023).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"806_CR49","doi-asserted-by":"publisher","first-page":"107129","DOI":"10.1016\/j.parkreldis.2024.107129","volume":"128","author":"R Shimasaki","year":"2024","unstructured":"Shimasaki, R. et al. Associations of cerebrospinal fluid monoamine metabolites with striatal dopamine transporter binding and 123I-meta-iodobenzylguanidine cardiac scintigraphy in Parkinson's disease: Multivariate analyses. Parkinsonism Relat. Disord. 128, 107129 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"806_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-017-0175-6","volume":"4","author":"L Tossici-Bolt","year":"2017","unstructured":"Tossici-Bolt, L. et al. [(123)I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Phys. 4, 8 (2017).","journal-title":"EJNMMI Phys."},{"key":"806_CR51","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00259-018-3976-5","volume":"45","author":"H Matsuda","year":"2018","unstructured":"Matsuda, H. et al. Japanese multicenter database of healthy controls for [(123)I]FP-CIT SPECT. Eur. J. Nucl. Med Mol. Imaging 45, 1405\u20131416 (2018).","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"806_CR52","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s12350-014-9916-2","volume":"21","author":"K Nakajima","year":"2014","unstructured":"Nakajima, K. et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J. Nucl. Cardiol. 21, 970\u2013978 (2014).","journal-title":"J. Nucl. Cardiol."},{"key":"806_CR53","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transpl."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00806-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00806-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00806-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T02:03:13Z","timestamp":1729648993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00806-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1038\/s41531-024-00806-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}